Your browser doesn't support javascript.
loading
The colibactin-producing Escherichia coli alters the tumor microenvironment to immunosuppressive lipid overload facilitating colorectal cancer progression and chemoresistance.
de Oliveira Alves, Nilmara; Dalmasso, Guillaume; Nikitina, Darja; Vaysse, Amaury; Ruez, Richard; Ledoux, Lea; Pedron, Thierry; Bergsten, Emma; Boulard, Olivier; Autier, Lora; Allam, Sofian; Motreff, Laurence; Sauvanet, Pierre; Letourneur, Diane; Kashyap, Pragya; Gagnière, Johan; Pezet, Denis; Godfraind, Catherine; Salzet, Michel; Lemichez, Emmanuel; Bonnet, Mathilde; Najjar, Imène; Malabat, Christophe; Monot, Marc; Mestivier, Denis; Barnich, Nicolas; Yadav, Pankaj; Fournier, Isabelle; Kennedy, Sean; Mettouchi, Amel; Bonnet, Richard; Sobhani, Iradj; Chamaillard, Mathias.
Afiliación
  • de Oliveira Alves N; ONCOLille, INSERM, Phycell, University of Lille, Lille, France.
  • Dalmasso G; Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Nikitina D; CNRS, Institute Pasteur, Paris, France.
  • Vaysse A; Laboratory of Clinical and Molecular Gastroenterology, Institute for Digestive Research, Lithuanian University of Health Sciences, Kaunas, Lithuania.
  • Ruez R; Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Plate-Forme Technologique Biomics, Paris, France.
  • Ledoux L; ONCOLille, INSERM, Phycell, University of Lille, Lille, France.
  • Pedron T; Réponse Inflammatoire et Spectrométrie de Masse-PRISM, University of Lille, Lille, France.
  • Bergsten E; Institut Pasteur, Inserm, Paris, France.
  • Boulard O; Institut Pasteur, Université Paris Cité, Paris, France.
  • Autier L; ONCOLille, INSERM, Phycell, University of Lille, Lille, France.
  • Allam S; ONCOLille, INSERM, Phycell, University of Lille, Lille, France.
  • Motreff L; ONCOLille, INSERM, Phycell, University of Lille, Lille, France.
  • Sauvanet P; Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Plate-Forme Technologique Biomics, Paris, France.
  • Letourneur D; Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Kashyap P; Institut Pasteur, Université Paris Cité, Paris, France.
  • Gagnière J; Department of Bioscience & Bioengineering, Indian Institute of Technology, Jodhpur, Rajasthan, India.
  • Pezet D; Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Godfraind C; Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Salzet M; Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Lemichez E; Réponse Inflammatoire et Spectrométrie de Masse-PRISM, University of Lille, Lille, France.
  • Bonnet M; Institut Pasteur, Université Paris Cité, Paris, France.
  • Najjar I; Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Malabat C; Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Plate-Forme Technologique Biomics, Paris, France.
  • Monot M; Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Plate-Forme Technologique Biomics, Paris, France.
  • Mestivier D; Institut Pasteur, Université Paris Cité, Bioinformatics and Biostatistics Hub, Plate-Forme Technologique Biomics, Paris, France.
  • Barnich N; Université Paris Est Créteil, Créteil, France.
  • Yadav P; Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Fournier I; Department of Bioscience & Bioengineering, Indian Institute of Technology, Jodhpur, Rajasthan, India.
  • Kennedy S; Réponse Inflammatoire et Spectrométrie de Masse-PRISM, University of Lille, Lille, France.
  • Mettouchi A; CNRS, Institute Pasteur, Paris, France.
  • Bonnet R; Institut Pasteur, Université Paris Cité, Paris, France.
  • Sobhani I; Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte (M2iSH), Centre de Recherche en Nutrition Humaine Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Chamaillard M; Université Paris Est Créteil, Créteil, France.
Gut Microbes ; 16(1): 2320291, 2024.
Article en En | MEDLINE | ID: mdl-38417029
ABSTRACT
Intratumoral bacteria flexibly contribute to cellular and molecular tumor heterogeneity for supporting cancer recurrence through poorly understood mechanisms. Using spatial metabolomic profiling technologies and 16SrRNA sequencing, we herein report that right-sided colorectal tumors are predominantly populated with Colibactin-producing Escherichia coli (CoPEC) that are locally establishing a high-glycerophospholipid microenvironment with lowered immunogenicity. It coincided with a reduced infiltration of CD8+ T lymphocytes that produce the cytotoxic cytokines IFN-γ where invading bacteria have been geolocated. Mechanistically, the accumulation of lipid droplets in infected cancer cells relied on the production of colibactin as a measure to limit genotoxic stress to some extent. Such heightened phosphatidylcholine remodeling by the enzyme of the Land's cycle supplied CoPEC-infected cancer cells with sufficient energy for sustaining cell survival in response to chemotherapies. This accords with the lowered overall survival of colorectal patients at stage III-IV who were colonized by CoPEC when compared to patients at stage I-II. Accordingly, the sensitivity of CoPEC-infected cancer cells to chemotherapies was restored upon treatment with an acyl-CoA synthetase inhibitor. By contrast, such metabolic dysregulation leading to chemoresistance was not observed in human colon cancer cells that were infected with the mutant strain that did not produce colibactin (11G5∆ClbQ). This work revealed that CoPEC locally supports an energy trade-off lipid overload within tumors for lowering tumor immunogenicity. This may pave the way for improving chemoresistance and subsequently outcome of CRC patients who are colonized by CoPEC.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Neoplasias Colorrectales / Policétidos / Microbioma Gastrointestinal Límite: Humans Idioma: En Revista: Gut Microbes Año: 2024 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Péptidos / Neoplasias Colorrectales / Policétidos / Microbioma Gastrointestinal Límite: Humans Idioma: En Revista: Gut Microbes Año: 2024 Tipo del documento: Article País de afiliación: Francia